跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,601 条关于
“KCNT1+ epilepsy”
全部
2,601
临床试验
2,080
药物
35
机构
9
资讯
477
去年
Actio Biosciences Receives FDA Clearance and Fast Track Designation for First-in-Class KCNT1 Epilepsy Treatment
前天
Jazz Pharmaceuticals Completes $820M Actio Biosciences Acquisition, Adding First-in-Class KCNT1 Epilepsy Candidate ABS-1230
上个月
Jazz Pharmaceuticals to Acquire Actio Biosciences for $820 Million, Securing First-in-Class KCNT1 Epilepsy Therapy ABS-1230
4个月前
Actio Biosciences Initiates Phase 1b/2 Trial of ABS-1230 for Rare Pediatric Epilepsy
去年
Actio Biosciences Raises $66M Series B to Advance Rare Disease Programs Targeting Ion Channel Disorders
去年
Atalanta Therapeutics Secures $97 Million to Advance RNAi Therapies for Neurological Disorders
3个月前
Servier Enrolls First Patient in Phase Ib/II Trial of ASO Therapy for KCNT1-Related Pediatric Epilepsy
28天前
Eight-month-old becomes first in world to receive precision medicine for KCNT1-related catastrophic epilepsy
9个月前
Citizen Health and UCB Launch Strategic Partnership to Accelerate Epilepsy and Rare Disease Drug Development Using AI
去年
UCB Presents Comprehensive Epilepsy Research Portfolio at International Epilepsy Congress 2025
第 1 页,共 48 页
上一页
下一页